News

Precision Antibody is pleased to announce the recent article published in Cancers 2020, by Konig et al entitled “Expression of AR-V7 (androgen receptor variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients”.

A&G Pharmaceutical, Inc (A&G), with its Custom Antibody Division Precision Antibody has developed mouse monoclonal antibodies (mAbs) against COVID-19 antigens; Spike protein S1 and nucleocapsid protein (N-protein).

Precision Antibody contributes to the development of novel antibody reagents for the RAS signaling network The National Cancer Institute (NCI)’s RAS initiative has been working with the Office of Cancer Clinical Proteomics Research (OCCPR) to launch a proteomic assay development and characterization project targeting RAS-associated pathways. The goal of this research, which aligns with one […]

Precision Antibody and A&G Pharmaceutical are pleased to announce the publication, in PLOS One, of the results of their collaborative study about the identification of Prostaglandin F2 receptor negative regulator as a cancer cell surface target and the isolation of internalizing antibody for antibody drug conjugate development.

Precision Antibody’s proprietary technology develops fully human antibodies in ~60 days Precision Antibody has an exclusive license agreement with trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci. Precision Antibody has developed a proprietary method to develop a strong immune response against therapeutic targets in three weeks, enabling fully human therapeutic antibody development […]